Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 7Phase 1/2 5Phase 3 1

Status

Completed 5

Sponsor Class

NIH 6INDUSTRY 5OTHER 3

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Breast 2Gynecologic 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Ovarian Neoplasms 1Ovarian Diseases 1Melanoma 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × entinostat × Clear all
NCT03280563 2025-11-10

MORPHEUS HR+BC

Hoffmann-La Roche

Phase 1/2 Completed
144 enrolled 25 charts
Breast

Breast Neoplasms

NCT02437136 2025-03-20

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)

Syndax Pharmaceuticals

Phase 1/2 Completed
191 enrolled 26 charts
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT02708680 2024-12-04

Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In

Syndax Pharmaceuticals

Phase 1/2 Completed
89 enrolled 16 charts
Breast

Breast Neoplasms

NCT02915523 2024-01-10

Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer

Syndax Pharmaceuticals

Phase 1/2 Completed
140 enrolled 25 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Diseases, Ovarian Neoplasms

NCT00602030 2022-08-22

Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC

Syndax Pharmaceuticals

Phase 1/2 Completed
141 enrolled 24 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡